Prestige BioPharma (PBP) is a Singapore based biopharmaceutical company specializing in the discovery and development of innovative biologics and biosimilars. The company's Herceptin Biosimilar, HD201, is currently projected to launch in the 2022 market, and is rapidly growing as a leading global biopharmaceutical company. Based on the cutting-edge technologies and GMP manufacturing facilities, the company's current biosimilar pipeline includes: Herceptin Biosimilar (HD201), Avastin Biosimilar (HD204), Humira Adalimumab (PBP1502), Denosumab Biosimilar (PBP1601), Aflibercept Biosimilar (PBP1602), and Eculizumab Biosimilar (PBP1603). The primary focus of current PBP’s R&D is oncology and immune disorders, developing new and similar antibody drugs for solid tumor, pancreatic cancer, and arthritis. In parallel with our efforts to enhance safety, efficacy, and affordability of existing antibody therapeutics, PBP thrives to search for new targets and candidates with a goal to free mankind from devastating diseases Established on core values cherishing life and fostering the spirit of philanthropy, Prestige BioPharma promises to grow everyday to make our dream come true.